COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Optical Detection of Malignancy During Percutaneous Interventions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01730365
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : April 11, 2016
Information provided by (Responsible Party):
Philips Healthcare

Brief Summary:
Investigation of application possibilities of optical spectroscopy within the field of oncology. Optical spectroscopy enables the possibility to specifically differentiate between different (human) tissues. The hypothesis is that incorporation of this technique into existing medical devices (e.g. biopsy needle) would enlarge the accuracy and reliability of these devices. The purpose is to improve and speed up the diagnostics and therapy of the malignancies.

Condition or disease Intervention/treatment
Pulmonary Coin Lesion Colon Cancer Liver Metastasis Breast Cancer Procedure: Core biopsy procedure

Detailed Description:

Primary Objective:

In this observational study the investigators aim to evaluate whether optical spectroscopy can correctly diagnose malignant tissue in the existing clinical workflow of percutaneous interventions in lung, liver, and breast.

Secondary Objective:

During the measurement procedure, possible improvements of the measurement hardware will be recorded. Analysis of this documentation will provide information for possible alterations of hardware design for improved clinical applicability in the future. Special attention will be paid to observe how the procedure fits in the standard workflow of the radiologist.

Layout table for study information
Study Type : Observational
Actual Enrollment : 104 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques
Study Start Date : October 2012
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Group/Cohort Intervention/treatment
Histological biopsy procedures
Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
Procedure: Core biopsy procedure
Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
Other Names:
  • Histological biopsy procedure
  • Standard biopsy procedure

Primary Outcome Measures :
  1. Differentiation between normal and malignant tissue [ Time Frame: Day 0 ]
    Statistical analysis of the difference between diffuse reflectance spectra obtained at normal and malignant measurement locations

Biospecimen Retention:   Samples Without DNA
Biopsies are taken from the enrolled patients and these biopsies are send to the pathology department for histopathological analysis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Eligible patients are all patients, who are scheduled for a standard core biopsy of lung, liver or breast; or percutaneous RFA of liver in the Netherlands Cancer Institute (NKI-AvL), Amsterdam, The Netherlands. In the enrollment process the "patient informatie" will be used and the informed consent must be signed prior to the intervention.

Inclusion Criteria:

  • Patients with a suspicious lesion in lung or liver who are scheduled for a standard core biopsy procedure
  • Patient planned for percutaneous RFA of colorectal liver metastasis
  • Written informed consent
  • Patients ≥ 18 years old
  • Breast patients with a BIRADS score 4 or 5

General Exclusion criteria:

  • Patients who have higher risk of bleeding
  • Patients with suspected sensitivity to light; e.g. patients who have had photodynamic therapy

Breast Specific Exclusion criteria:

  • Patients who have a history of breast cancer and/or who have received prior chemotherapy, endocrine therapy, or radiation therapy
  • Patients who have breast implants
  • Patients needing a stereotactic breast biopsy (i.e. non palpable-, ultrasound opaque lesions)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01730365

Layout table for location information
Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis
Amsterdam, Noord-Holland, Netherlands, 1066 CX
Sponsors and Collaborators
Philips Healthcare
Layout table for investigator information
Principal Investigator: Theo Ruers, MD Nederlands Kanker Instituut/Antonie van leeuwenhoek Ziekenhuis
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Philips Healthcare Identifier: NCT01730365    
Other Study ID Numbers: NL40578.031.12
First Posted: November 21, 2012    Key Record Dates
Last Update Posted: April 11, 2016
Last Verified: April 2016
Keywords provided by Philips Healthcare:
Additional relevant MeSH terms:
Layout table for MeSH terms
Solitary Pulmonary Nodule
Lung Diseases
Respiratory Tract Diseases